Andrea Botticelli
@DottBotticelliA
Followers
161
Following
464
Media
14
Statuses
125
MD, PhD, assistant Professor, Sapienza University of Rome, breast cancer, Head and neck cancer, precision medicine @sapienzaroma
Rome
Joined March 2023
Adding #tucatinib to trastuzumab+pertuzumab maintenance in first-line HER2+ breast cancer treatment improves PFS. Will these results have an impact on the standard treatment paradigm? And how will they fit with recent DESTINY-Breast09 data? @OncoAlert
NEWS FROM Industry: HER2CLIMB-05 Update Source: Pfizer announcement, report by Business wire https://t.co/P75uFNuhpI Pfizer announced positive topline results from the Phase 3 HER2CLIMB-05 trial, which evaluated the addition of the tyrosine kinase inhibitor tucatinib to
1
6
23
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial https://t.co/GMjBHTgCxW The ROME trial, a multicenter randomized phase 2 study, evaluated the benefit of tumor-agnostic precision oncology by comparing tailored treatment (TT) guided by
2
9
19
Out in @eClinicalMed a network M-A evaluating treatment strategies after PD on CDK4/6i in HR+/HER2− mBC Results support biomarker-driven algorithm and are relevant since head-to-head trials are unlikely to be conducted! Congrats @RobertoBuonaiu3 @CarmineDeA1 👏 @OncoAlert
1
16
49
🏅Optimal treatment sequencing after CDK4/6i + ET in HR+/HER2− MBC remains unclear due to lack of head-to-head trials 🤔 💻We conducted a systematic review & NMA to guide evidence-based decisions. 📰Read more: https://t.co/3QUFaERmUw
@OncoAlert
@oncodaily
@eClinicalMed
3
28
71
@CarmineDeA1 @OncoAlert @oncodaily @eClinicalMed @vitti10 @CarmenCriscit @LMalorni @antgiorda @ACaltavituro @MicheleDelauren @DottBotticelliA @LGerratana @RobertoBuonaiu3 Great effort led by super @CarmineDeA1 💪
0
2
6
Herculean effort in @NatureMedicine from 🇮🇹 (@Roma) group re: tumor-agnostic oncology strategy. Benefit likely higher w/potent drugs in the future. https://t.co/SYUCAzLkVZ
@curijoey @PAscierto @oncologiaroma @myESMO PS: plz don't confuse @DottBotticelliA with @AndreaBocelli !!!
nature.com
Nature Medicine - In the proof-of-concept phase 2 ROME trial, comprehensive genomic profiling followed by molecular tumor board evaluation and randomization of patients with metastatic solid cancer...
🇮🇹 The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care. @myESMO @IEOufficiale @LaStatale
0
11
37
@curijoey @myESMO @IEOufficiale @LaStatale @DottBotticelliA @PTarantinoMD @AIOMtweet @mur_gov_ @MinisteroSalute @DrChoueiri Wow! Huge congratulations! This is a very important study for #precisiononcology 👏🏼👏🏼👏🏼
0
3
9
🇮🇹 The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care. @myESMO @IEOufficiale @LaStatale
8
49
201
I had the chance to contribute to pts enrolment in the #ROME trial during my residency and found the concept truly groundbreaking. I'm glad to see the main results now published in @NatureMedicine!! The phase 2 ROME trial compared genomically matched therapies (TT) with standard
0
7
25
When dreams come true!!!! Mutational approach is the road... @NatureMedicine @curijoey @oncologiaroma @puglisi_fabio @ChiaraCrem1 @SapienzaRoma
0
0
1
@DottBotticelliA @AACR @oncologiaroma @curijoey @UmbertoMalapel1 @saralonardi @paoloascierto Great question, Andrea. Each biopsy type has its place in precision medicine. Liquid biopsies offer a non-invasive option and can provide real-time insights into tumor dynamics and genetic mutations. However, solid biopsies remain crucial for histopathological confirmation and
0
1
1
Biopsia liquida, tissutale, o entrambe?
0
1
5
Liquid or solid biopsy? @clinicalcancerresearch @AACR @oncologiaroma @curijoey @UmbertoMalapel1 @saralonardi @paoloascierto
1
4
18
Out in @Annals_Oncology A-BRAVE trial (adj avelumab in high-risk eTNBC): DFS HR 0.81 ➡️ Not significant❌ OS (HR 0.66) & DDFS (HR 0.70) benefit ✅ → PD-L1 prognostic, not predictive https://t.co/vKyCX1ZEja
@OncoAlert @UniPadova @vitti10
0
3
13
FDA approves a treatment for adults with resectable locally advanced head and neck squamous cell cancer whose tumors express PD-L1. https://t.co/AECLlZ3r4R
2
9
16
Association between BRCA1/2 pathogenic/likely pathogenic variants and outcomes in young #breastcancer Excellent job presented by super Angela Toss #ASCO25 Another great contribution related to the BCY initiative led by amazing @matteolambe
@OncoAlert #OncoAlert
1
13
32
0
0
2
Thank you. Fabulous session and honored to participate with my esteemed colleagues! Congrats and thanks to @curijoey for organizing and chairing our session. #AACR25 @cityofhope
#AACR25 #ADC tour de force continues with talks by @curijoey, Sara Hurvitz @fredhutch, and @hoperugo on Challenges and Opportunities in the Development of Next Generation Antibody Drug Conjugates… and peptide drug conjugates!
0
3
11
0
3
5
The impact of concordance of molecular profile on tissue and liquid biopsy on response to target therapy and immunotherapy : a posthoc analysis of the Rome trial !A novel challange ? @AACR @curijoey @BenWestphalen @VivekSubbiah @oncologiaroma
0
4
8